Skip to content

Kyverna Therapeutics, Inc. KYTX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$199M+15.7%
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
$263K+69.7%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$3.02M-15.9%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$2.9M-65.9%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$738K+37.7%
Vor Biopharma logo
Vor BiopharmaVOR
$307K-92.8%

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$498.52M+276%
Enterprise value$475.49M+475%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s operating lease liabilities (current)?
Kyverna Therapeutics, Inc. (KYTX) reported operating lease liabilities (current) of $1.76M in Q1 2026.
How has Kyverna Therapeutics, Inc.'s operating lease liabilities (current) changed year-over-year?
Kyverna Therapeutics, Inc.'s operating lease liabilities (current) decreased by 42.7% year-over-year, from $3.08M to $1.76M.
What is the long-term trend for Kyverna Therapeutics, Inc.'s operating lease liabilities (current)?
Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s operating lease liabilities (current) has grown at a 36.5% compound annual growth rate (CAGR), from $1.96M to $3.66M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.